E7080

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Melanoma

Conditions

Metastatic Melanoma

Trial Timeline

Jul 1, 2005 → May 1, 2015

About E7080

E7080 is a phase 1 stage product being developed by Eisai for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00121680. Target conditions include Metastatic Melanoma.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Melanoma were approved

Approved (20) Terminated (8) Active (0)
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
EnzalutamideAstellas PharmaApproved
Enfortumab VedotinAstellas PharmaApproved
EligardAstellas PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT01268293Phase 1Completed
NCT00280397Phase 1Completed
NCT00121680Phase 1Completed

Competing Products

20 competing products in Metastatic Melanoma

See all competitors